Convalescent Blood Products in COVID-19: A Narrative Review.

COVID-19 SARS-CoV-2 convalescent blood products evidence review

Journal

Therapeutic advances in infectious disease
ISSN: 2049-9361
Titre abrégé: Ther Adv Infect Dis
Pays: England
ID NLM: 101606715

Informations de publication

Date de publication:
Historique:
received: 13 07 2020
accepted: 26 08 2020
entrez: 5 10 2020
pubmed: 6 10 2020
medline: 6 10 2020
Statut: epublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has left the world in a state of desolation with overburdening public health systems in a short period. Finding possible preventative and therapeutic measures to counter severe respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has been the priority. A possible solution is convalescent blood products (CBP), primarily convalescent plasma (CP) and immunoglobulins, as an adjunctive therapy. CBP has been tried on the previous coronavirus epidemics with severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Therefore, we reviewed the clinical utility of CBP and available evidence in COVID-19. We found some of the current anecdotal studies demonstrate promising therapeutic potential, but many of these studies do not meet the academic rigours to substantiate its use with confidence. However, the compassionate use of CBP in critically ill COVID-19 patients can be an option while we await a definitive answer from ongoing randomised clinical trials.

Identifiants

pubmed: 33014364
doi: 10.1177/2049936120960646
pii: 10.1177_2049936120960646
pmc: PMC7513012
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

2049936120960646

Informations de copyright

© The Author(s), 2020.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declare that there is no conflict of interest.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Rev Med Virol. 2005 Nov-Dec;15(6):407-18; discussion 418-21
pubmed: 16211552
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Antiviral Res. 2017 Jul;143:30-37
pubmed: 28389142
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26
pubmed: 24778221
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
N Engl J Med. 2020 May 22;:
pubmed: 32445440
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Vox Sang. 2020 Apr 2;:
pubmed: 32240549
Sci Rep. 2016 Aug 19;6:31629
pubmed: 27538452
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8
pubmed: 26216974
JAMA. 2020 Aug 4;324(5):524
pubmed: 32530454
Sci Transl Med. 2014 Apr 30;6(234):234ra59
pubmed: 24778414
J Virol. 2014 Jul;88(14):7796-805
pubmed: 24789777
Clin Diagn Lab Immunol. 2001 Sep;8(5):859-63
pubmed: 11527792
Transfus Apher Sci. 2003 Aug;29(1):101
pubmed: 12952008
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
J Infect Dis. 2016 May 15;213(10):1557-61
pubmed: 26941283
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Vox Sang. 2020 Apr 2;:
pubmed: 32240545
BMJ. 2020 Mar 26;368:m1256
pubmed: 32217555
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
J Virol. 2018 Jan 30;92(4):
pubmed: 29212926
Zhonghua Yi Xue Za Zhi. 2003 Jun 25;83(12):1018-22
pubmed: 12899773
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Clin Microbiol Rev. 2000 Oct;13(4):602-14
pubmed: 11023960
Clin Infect Dis. 2020 Mar 26;:
pubmed: 32215622
Ann Lab Med. 2016 Jul;36(4):393-5
pubmed: 27139619
Nat Med. 2020 Sep 15;:
pubmed: 32934372
Hong Kong Med J. 2003 Jun;9(3):199-201
pubmed: 12777656
J Med Virol. 2020 May 1;:
pubmed: 32356910
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
J Clin Med. 2020 Feb 26;9(3):
pubmed: 32110875
J Clin Invest. 1944 Jul;23(4):531-40
pubmed: 16695129
Emerg Infect Dis. 2017 Jul;23(7):1079-1084
pubmed: 28585916
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Aging (Albany NY). 2020 Apr 22;12(8):6536-6542
pubmed: 32320384
Blood Transfus. 2016 Mar;14(2):152-7
pubmed: 26674811
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12
pubmed: 23401516
Transfus Med Rev. 2020 Jul;34(3):141-144
pubmed: 32359789
Vox Sang. 2020 Apr 20;:
pubmed: 32311760
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
JAMA. 2020 Aug 4;324(5):455-457
pubmed: 32492105

Auteurs

Keegan Chua Vi Long (K)

School of Medicine, National University of Ireland, Galway, Ireland.

Abida Sayed (A)

Medicine Department, Avalon University School of Medicine, Willemstad, Curacao, Netherlands Antilles.

Priyanka Karki (P)

Nobel Medical College Teaching Hospital, Kanchanbari, Biratnagar, Morang, Nepal.

Yogesh Acharya (Y)

Research Fellow, Vascular and Endovascular Department, Western Vascular Institute, National University of Ireland, Galway, Ireland.

Classifications MeSH